Evidence map›Paper›PMID 38146355›Full record

ArticleBlood cell therapy2023

Association of

Makoto Onizuka, Eri Kikkawa, Shinichiro Machida, Masako Toyosaki, Rikio Suzuki, Daisuke Ogiya, Yasuyuki Aoyama, Jun Amaki, Kaito Harada, Ryujiro Hara and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Blood cell therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. [Research progress on copy number alterations in pediatric B-cell acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Eri KikkawaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Shinichiro MachidaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Masako ToyosakiDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Rikio SuzukiDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Daisuke OgiyaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Yasuyuki AoyamaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Jun AmakiDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Kaito HaradaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Ryujiro HaraDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Sawako ShiraiwaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Yoshiaki OgawaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Hiroshi KawadaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Kiyoshi AndoDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Tokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most important prognostic factor for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) is minimal residual disease (MRD). Previous studies have reported copy number variants of genes such as

Indexed as

CDKN2A/2Bcopy number alterationIKZF1Ph+ALL

Identifiers

PMID38146355
PMCPMC10749213
OpenAlexW4386642119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.